financetom
Business
financetom
/
Business
/
Nordson Fiscal Q2 Earnings Fall; Updates Guidance; Shares Drop After-Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nordson Fiscal Q2 Earnings Fall; Updates Guidance; Shares Drop After-Hours
May 20, 2024 2:14 PM

04:58 PM EDT, 05/20/2024 (MT Newswires) -- Nordson ( NDSN ) reported fiscal Q2 adjusted earnings Monday of $2.34 per diluted share, down from $2.45 a year earlier.

Analysts surveyed by Capital IQ expected $2.32.

Sales for the quarter ended April 30 was $650.6 million, up from $650.2 million a year earlier.

Analysts surveyed by Capital IQ expected $665.1 million.

The company said it expects fiscal Q3 adjusted EPS of $2.25 to $2.40 on revenue of $645 million to $670 million. Analysts surveyed by Capital IQ expected $2.73 for EPS on revenue of $708 million.

Nordson ( NDSN ) now expects fiscal year 2024 adjusted EPS of $9.35 to $9.75 on revenue growth of flat to 2%, compared with $10.00 to $10.50 for EPS on revenue growth of 4% to 7% growth previously. Analysts expected $10.24 for EPS.

Shares of the company fell more than 11% in recent after-hours activity.

Price: 238.60, Change: -29.81, Percent Change: -11.11

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain
Mar 18, 2025
09:03 AM EDT, 03/18/2025 (MT Newswires) -- Dogwood Therapeutics ( DWTX ) said Tuesday it has begun dosing patients in a phase 2b trial testing Halneuron for chemotherapy-induced neuropathic pain. The company said it plans to enroll 100 patients by Q4 when it expects to conduct an interim analysis to assess trial progress and make any necessary adjustments. Shares of...
CME Group to launch European rapeseed oil futures
CME Group to launch European rapeseed oil futures
Mar 18, 2025
PARIS (Reuters) - Financial markets operator CME Group ( CME ) said on Tuesday that it plans to launch cash-settled futures for European rapeseed oil next month, using an Argus Media index for Dutch prices. The new product will start trading on April 28, subject to regulatory approval, through CME's Chicago Board of Trade exchange, the company said in a...
Dr. Reddy's, Alvotech Say FDA Accepts Biologic License Application for Bone Drug Biosimilar
Dr. Reddy's, Alvotech Say FDA Accepts Biologic License Application for Bone Drug Biosimilar
Mar 18, 2025
09:04 AM EDT, 03/18/2025 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) and Alvotech ( ALVO ) said Tuesday that the US Food and Drug Administration has accepted a biologic license application submission for AVT03, a proposed biosimilar of bone disease treatments Prolia and Xgeva. Dr. Reddy's and Alvotech ( ALVO ) last year entered into a license and supply agreement...
Putin tells Russian business not to count on fully free trade even if Western sanctions are eased
Putin tells Russian business not to count on fully free trade even if Western sanctions are eased
Mar 18, 2025
MOSCOW (Reuters) - President Vladimir Putin told Russian business leaders on Tuesday not to count on fully free trade or movement of capital being restored in the event of Western sanctions on Russia being eased. Our competitors will always want to weaken and contain us, Putin told a meeting with Russian businessmen. Even if one side will make a gesture...
Copyright 2023-2026 - www.financetom.com All Rights Reserved